CTRI/2021/03/031844尚未招募未知
Patient specific three-dimensional printed models of aberrant anatomy for surgical planning of anorectal malformation
AIIMS Delhi0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male patient with anorectal anomaly with colostomy done in neonatal period and waiting for a definitive repair in whom the pressure augmented colostogram does not reveal an obvious urethral communication with the terminal portion of bowel.
排除标准
- •1. Patients in whom a prior lower abdominal/pelvic surgery/urological has been done before.
- •2. Patients in whom a prior surgery in the perineum or exploration has been done before.
- •3. Patients having a concomitant cardiac anomaly severe enough to preclude administering
- •sedation or anesthesia as decided by a consultant anesthetist.
- •4. Patients in whom urethral catheterization fails by a trained surgical resident with a minimum
- •of 3 yearsâ?? experience after medical graduation (senior resident).
- •5. ARM associated with caudal regression syndrome (a disorder that impairs the development
- •of the lower (caudal) half of the body. Affected areas can include the lower back, sacrum, pelvis, limbs, the genitourinary tract, and the gastrointestinal tract.
研究者
相似试验
进行中（未招募）
3 期
A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Japanese Adults With HypoparathyroidismHypoparathyroidismJPRN-jRCT2051210058Sibley Christopher12
进行中（未招募）
不适用
Randomized, open label, multicentric phase III trial evaluating the benefit of a sequential regimen associating FEC100 and Ixabepilone in adjuvant treatment of non metastatic, poor prognosis breast cancer defined as triple-negative tumor (HER2 negative - ER negative - PR negative) or HER2 negative and PR negative tumor; in node positive or node negative patients. - TavIxEUCTR2006-006494-24-BEFédération Nationale des Centres de Lutte Contre le Cancer2,500
招募中
3 期
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection2024-510704-37-00Unicancer1,000
进行中（未招募）
1 期
Randomized, open label, multicentric phase III trial evaluating the benefit of a sequential regimen associating FEC100 and Ixabepilone in adjuvant treatment of non metastatic, poor prognosis breast cancer defined as triple-negative tumor (HER2 negative - ER negative - PR negative) or HER2 negative and PR negative tumor; in node positive or node negative patients. - TavIxnon-metastatic operable breast cancerMedDRA version: 9.1 Level: LLT Classification code 10006192 Term: Breast cancer NOSEUCTR2006-006494-24-FRFédérationa Nationale des Centres de Lutte Contre le Cancer2,500
进行中（未招募）
不适用
Study to evaluate the safety of two doses of Novartis Meningococcal Group B Vaccine when administered to healthy adults from 18 to 50 Years of age and to collect blood donations to develop vaccines against Neisseria MeningitidisEUCTR2014-002972-95-PLovartis Pharma Services AG